Abstract:e13562 Background: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive therapy in cancer patients and impose substantial morbidity and mortality risks. We analyzed National Inpatient Sample (NIS) database to understand the trend in FN and predict mortality in cancer patients who experienced FN using a machine learning (ML) approach. Methods: We used the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) data. Cancer discharges were identified using the HCUP Clinical Classifications Software (CCS) categorizations (11-45), within which FN patients were identified with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (ICD-9-CM: 7806 and 288, 2841 or 1125). We examined trends in FN discharges and mortality rates using during 2003 – 2015, and then built various models on NIS 2013 data to predict mortality. Results: The percentage of discharges secondary to cancer-related FN kept increasing from 0.2% in 2003 and stabilized around 2% since 2010. However, associated cost has continued to rise (average cost of $36,853 vs $105,912 respectively, in 2003 and 2015). The unadjusted mortality rate also kept increasing from 2.2% in 2003 and has stabilized around ~ 4.2% since 2010. The logistic regression model showed significantly higher odds of mortality with advancing age (2.8%, 3.8%, 7%, 8.3% respectively, for age group 18-44, 45-64, 65-84, 85+). Presence of bacteremia compared to no bacteremia (4.5 vs, 3.3, P < 0.01), non-teaching hospitals compared to teaching hospital (4.9% vs, 4.3%, P < 0.01), and comorbidities such as hypertension, paralysis, hypothyroidism, depression showed higher risk of mortality (P < 0.05). Patients admitted over weekend and transferred from another institute had higher odds of mortality (P < 0.01). Conclusions: Even in this era of widespread use of granulocyte colony-stimulating factor for primary prophylaxis and less cytotoxic immunotherapy, mortality from FN remains significantly higher and continues to impose significant financial burden. Identification of risk factors and predicting mortality risk will help clinicians take better therapeutic decisions and thus patient survival.

Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea

Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy

A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora.

Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

A clinicopathological analysis of neoadjuvant therapy for early breast cancer complicated with febrile neutropenia

Outcomes in 102 patients that present to the emergency department with chemotherapy-induced febrile neutropenia

Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens

Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer

Clinical Analysis of High-Risk Primary and Metastatic Breast Cancer Patients with Neutropenia and Fever after High-Dose Chemotherapy

[Neoadjuvant Chemotherapy Using Epirubicin, Cyclophosphamide and Fluorouracil: Neutropenia and Elevation of Transaminase, and Their Management].

Risk of Mortality in Adult Cancer Febrile Neutropenia Patients with a Machine Learning Approach.

Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2)

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling

Febrile Neutropenia and Its Associated Hospitalization in Breast Cancer Patients on Docetaxel-Containing Regimen: A Retrospective Cohort Study on Duration of Prophylactic GCSF Administration

Clinical and Microbiological Characteristics of Febrile Neutropenia During Induction Chemotherapy in Adults With Acute Leukemia

Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients

Knowledge, attitude and practice towards chemotherapy-related neutropenia and febrile neutropenia among breast cancer patients

Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer

Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences